Current progress in using vitamin D and its analogs for cancer prevention and treatment

Expert Review of Anticancer Therapy

Volumn 12, Issue 6, 2012, Pages 811-837

  Cheung, Florence S G ^a   Lovicu, Frank J ^a   Reichardt, Juergen K V ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b JAMES COOK UNIVERSITY   (Australia)

Author keywords

calcitriol; cancer risks; differentiation; DN 101; epidemiology; pharmacokinetics; polymorphisms; proliferation regulation; VDR; vitamin D analog

Indexed keywords

25 HYDROXYVITAMIN D; ANTINEOPLASTIC AGENT; CALCITRIOL; CD 578; CY 616; DEXAMETHASONE; DOCETAXEL; DOXERCALCIFEROL; ELOCALCITOL; ESTRAMUSTINE; FDB 198E; GEFITINIB; MITOXANTRONE; OXYGENASE; PACLITAXEL; PARICALCITOL; PLACEBO; PREDNISONE; SEOCALCITOL; SW 123; UNCLASSIFIED DRUG; VITAMIN D; VITAMIN D DERIVATIVE; WU 515; WY 1113;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CALCIUM INTAKE; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CASTRATION RESISTANT PROSTATE CANCER; COLON CANCER; DISEASE ASSOCIATION; DNA POLYMORPHISM; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; LIVER CELL CARCINOMA; LUNG METASTASIS; MALIGNANT NEOPLASTIC DISEASE; MITOSIS INHIBITION; MULTIPLE CYCLE TREATMENT; NONHUMAN; PANCREAS CANCER; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RECEPTOR GENE; REVIEW; RISK ASSESSMENT; SINGLE DRUG DOSE; SOLID TUMOR; SUN EXPOSURE; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN D METABOLISM; VITAMIN D RECEPTOR GENE; VITAMIN INTAKE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VITAMIN D;

EID: 84862906896     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.53     Document Type: Review

References (137)

1. Jones G. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin. Dial. 20(4), 316-324 (2007).
2. Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int. J. Epidemiol. 9(3), 227-231 (1980).
3. Grant WB, Garland CF. A critical review of studies on vitamin D in relation to colorectal cancer. Nutr. Cancer 48(2), 115-123 (2004).
4. Grant WB. An ecological study of cancer incidence and mortality rates in France with respect to latitude, an index for vitamin D production. Dermatoendocrinol. 2(2), 62-67 (2010).
5. Loke TW, Sevfi D, Khadra M. Prostate cancer incidence in Australia correlates inversely with solar radiation. BJU Int. 108(Suppl. 2), 66-70 (2011).
6. Gilbert R, Metcalfe C, Oliver SE et al. Life course sun exposure and risk of prostate cancer: population-based nested case-control study and meta-ana lysis. Int. J. Cancer 125(6), 1414-1423 (2009).
7. John EM, Dreon DM, Koo J, Schwartz GG. Residential sunlight exposure is associated with a decreased risk of prostate cancer. J. Steroid Biochem. Mol. Biol. 89-90(1-5), 549-552 (2004).
8. Anderson LN, Cotterchio M, Kirsh VA, Knight JA. Ultraviolet sunlight exposure during adolescence and adulthood and breast cancer risk: a population-based case-control study among Ontario women. Am. J. Epidemiol. 174(3), 293-304 (2011).
9. Grant WB. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int. J. Cancer 120(5), 1123-1128 (2007).
10. Grant WB. Does solar ultraviolet irradiation affect cancer mortality rates in China? Asian Pac. J. Cancer Prev. 8(2), 236-242 (2007).
11. Kinoshita S, Wagatsuma Y, Okada M. Geographical distribution for malignant neoplasm of the pancreas in relation to selected climatic factors in Japan. Int. J. Health Geogr. 6, 34 (2007).
12. Grant WB. The effect of solar UVB doses and vitamin D production, skin cancer action spectra, and smoking in explaining links between skin cancers and solid tumours. Eur. J. Cancer 44(1), 12-15 (2008).
13. Wei MY, Giovannucci EL. Vitamin D and multiple health outcomes in the Harvard cohorts. Mol. Nutr. Food Res. 54(8), 1114-1126 (2010).
14. Oh K, Willett WC, Wu K, Fuchs CS, Giovannucci EL. Calcium and vitamin D intakes in relation to risk of distal colorectal adenoma in women. Am. J. Epidemiol. 165(10), 1178-1186 (2007).
15. Kampman E, Giovannucci E, Van 't Veer P et al. Calcium, vitamin D, dairy foods, and the occurrence of colorectal adenomas among men and women in two prospective studies. Am. J. Epidemiol. 139(1), 16-29 (1994).
16. Kearney J, Giovannucci E, Rimm EB et al. Calcium, vitamin D, and dairy foods and the occurrence of colon cancer in men. Am. J. Epidemiol. 143(9), 907-917 (1996).
17. Giovannucci E, Rimm EB, Wolk A et al. Calcium and fructose intake in relation to risk of prostate cancer. Cancer Res. 58(3), 442-447 (1998).
18. Gilbert R, Martin RM, Beynon R et al. Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-ana lysis. Cancer Causes Control 22(3), 319-340 (2011).
19. Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J. Natl Cancer Inst. 94(17), 1301-1311 (2002).
20. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-ana lysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res. Treat. 121(2), 469-477 (2010).
21. Hollis BW, Johnson D, Hulsey TC, Ebeling M, Wagner CL. Vitamin D supplementation during pregnancy: double-blind, randomized clinical trial of safety and effectiveness. J. Bone Miner. Res. 26(10), 2341-2357 (2011).
22. Zittermann A, Scheld K, Stehle P. Seasonal variations in vitamin D status and calcium absorption do not influence bone turnover in young women. Eur. J. Clin. Nutr. 52(7), 501-506 (1998).
23. Salamone LM, Dallal GE, Zantos D, Makrauer F, Dawson-Hughes B. Contributions of vitamin D intake and seasonal sunlight exposure to plasma 25-hydroxyvitamin D concentration in elderly women. Am. J. Clin. Nutr. 59(1), 80-86 (1994).
24. Lee JE, Li H, Chan AT et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians' Health Study and a meta-ana lysis of prospective studies. Cancer Prev. Res. (Phila.) 4(5), 735-743 (2011).
25. Touvier M, Chan DS, Lau R et al. Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol. Biomarkers Prev. 20(5), 1003-1016 (2011).
26. Gandini S, Boniol M, Haukka J et al. Meta-ana lysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int. J. Cancer 128(6), 1414-1424 (2011).
27. Jenab M, Bueno-De-Mesquita HB, Ferrari P et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ 340, b5500 (2010).
28. Woolcott CG, Wilkens LR, Nomura AM et al. Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev. 19(1), 130-134 (2010).
29. Mezawa H, Sugiura T, Watanabe M et al. Serum vitamin D levels and survival of patients with colorectal cancer: post-hoc ana lysis of a prospective cohort study. BMC Cancer 10, 347 (2010).
30. Ng K, Meyerhardt JA, Wu K et al. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. J. Clin. Oncol. 26(18), 2984-2991 (2008).
31. Abbas S, Linseisen J, Slanger T et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer - results of a large case-control study. Carcinogenesis 29(1), 93-99 (2008).
32. Yao S, Sucheston LE, Millen AE et al. Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS ONE 6(2), e17251 (2011).
33. Grant WB. Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. J. Photochem. Photobiol. B 101(2), 130-136 (2010).
34. Eliassen AH, Spiegelman D, Hollis BW, Horst RL, Willett WC, Hankinson SE. Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses' Health Study II. Breast Cancer Res. 13(3), R50 (2011).
35. Freedman DM, Chang SC, Falk RT et al. Serum levels of vitamin D metabolites and breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol. Biomarkers Prev. 17(4), 889-894 (2008).
36. Barnett CM, Nielson CM, Shannon J et al. Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control 21(8), 1297-1303 (2010).
37. Ahn J, Peters U, Albanes D et al. Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J. Natl Cancer Inst. 100(11), 796-804 (2008).
38. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E. Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 67(9), 911-923 (2007).
39. Tuohimaa P, Tenkanen L, Ahonen M et al. Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer 108(1), 104-108 (2004).
40. Ahonen MH, Tenkanen L, Teppo L, Hakama M, Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 11(9), 847-852 (2000).
41. Porojnicu AC, Robsahm TE, Dahlback A et al. Seasonal and geographical variations in lung cancer prognosis in Norway. Does Vitamin D from the sun play a role? Lung Cancer 55(3), 263-270 (2007).
42. Zhou W, Heist RS, Liu G et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J. Clin. Oncol. 25(5), 479-485 (2007).
43. Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI. Serum 25-hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer Res. 70(21), 8587-8597 (2010).
44. Weinstein SJ, Yu K, Horst RL, Parisi D, Virtamo J, Albanes D. Serum 25-hydroxyvitamin D and risk of lung cancer in male smokers: a nested case-control study. PLoS ONE 6(6), e20796 (2011).
45. Skinner HG, Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS. Vitamin D intake and the risk for pancreatic cancer in two cohort studies. Cancer Epidemiol. Biomarkers Prev. 15(9), 1688-1695 (2006).
46. Giovannucci E, Liu Y, Rimm EB et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J. Natl Cancer Inst. 98(7), 451-459 (2006).
47. Stolzenberg-Solomon RZ, Hayes RB, Horst RL, Anderson KE, Hollis BW, Silverman DT. Serum vitamin D and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian screening trial. Cancer Res. 69(4), 1439-1447 (2009).
48. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol. 172(1), 81-93 (2010).
49. Helzlsouer KJ. Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am. J. Epidemiol. 172(1), 4-9 (2010).
50. Yetley EA, Pfeiffer CM, Schleicher RL et al. NHANES monitoring of serum 25-hydroxyvitamin D: a roundtable summary. J. Nutr. 140(11), 2030S-2045S (2010).
51. Looker AC, Johnson CL, Lacher DA, Pfeiffer CM, Schleicher RL, Sempos CT Vitamin D status: United States, 2001-2006. NCHS Data Brief 59, 1-8 (2011).
52. Vashi PG, Trukova K, Lammersfeld CA, Braun DP, Gupta D. Impact of oral vitamin D supplementation on serum 25-hydroxyvitamin D levels in oncology. Nutr. J. 9, 60 (2010).
53. Brookes AJ, Lehvaslaiho H, Siegfried M et al. HGBASE: a database of SNPs and other variations in and around human genes. Nucleic Acids Res. 28(1), 356-360 (2000).
54. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat. Rev. Cancer 7(9), 684-700 (2007).
55. Tong WM, Kallay E, Hofer H et al. Growth regulation of human colon cancer cells by epidermal growth factor and 1,25-dihydroxyvitamin D3 is mediated by mutual modulation of receptor expression. Eur. J. Cancer 34(13), 2119-2125 (1998).
56. Sancho E, Batlle E, Clevers H. Signaling pathways in intestinal development and cancer. Annu. Rev. Cell. Dev. Biol. 20, 695-723 (2004).
57. Palmer HG, Gonzalez-Sancho JM, Espada J et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell. Biol. 154(2), 369-387 (2001).
58. Pendas-Franco N, Aguilera O, Pereira F, Gonzalez-Sancho JM, Munoz A. Vitamin D and Wnt/beta-catenin pathway in colon cancer: role and regulation of DICKKOPF genes. Anticancer Res. 28(5A), 2613-2623 (2008).
59. Larriba MJ, Bonilla F, Munoz A. The transcription factors Snail1 and Snail2 repress vitamin D receptor during colon cancer progression. J. Steroid Biochem. Mol. Biol. 121(1-2), 106-109 (2010).
60. Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells: a crosstalk interrupted by vitamin D3. Oncogene 28(44), 3892-3902 (2009).
61. Cheung FSG, Reichardt JKV. Molecular biology of vitamin D metabolism and skin cancer. In: Vitamin D and Cancer. Trump DL, Johnson CS (Eds). Springer, NY, USA, 191-219 (2011).
62. Ordonez-Moran P, Larriba MJ, Palmer HG et al. RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J. Cell. Biol. 183(4), 697-710 (2008).
63. Dunn KL, Espino PS, Drobic B, He S, Davie JR. The Ras-MAPK signal transduction pathway, cancer and chromatin remodeling. Biochem. Cell. Biol. 83(1), 1-14 (2005).
64. Mccarthy K, Laban C, Bustin SA et al. Expression of 25-hydroxyvitamin D-1- alpha-hydroxylase, and vitamin D receptor mRNA in normal and malignant breast tissue. Anticancer Res. 29(1), 155-157 (2009).
65. Townsend K, Evans KN, Campbell MJ, Colston KW, Adams JS, Hewison M. Biological actions of extra-renal 25-hydroxyvitamin D-1alpha-hydroxylase and implications for chemoprevention and treatment. J. Steroid Biochem. Mol. Biol. 97(1-2), 103-109 (2005).
66. Lopes N, Sousa B, Martins D et al. Alterations in vitamin D signalling and metabolic pathways in breast cancer progression: a study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions. BMC Cancer 10, 483 (2010).
67. Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol. Pharmacol. 76(4), 702-709 (2009).
68. Marik R, Fackler M, Gabrielson E et al. DNA methylation-related vitamin D receptor insensitivity in breast cancer. Cancer Biol. Ther. 10(1), 44-53 (2010).
69. Fischer D, Seifert M, Becker S et al. 25-hydroxyvitamin D3 1alpha-hydroxylase splice variants in breast cell lines MCF-7 and MCF-10. Cancer Genomics Proteomics 4(4), 295-300 (2007).
70. Zinser GM, Suckow M, Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. J. Steroid Biochem. Mol. Biol. 97(1-2), 153-164 (2005).
71. Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19(44), 5091-5097 (2000).
72. Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J. Biol. Chem. 276(12), 9101-9107 (2001).
73. Sergeev IN. Calcium signaling in cancer and vitamin D. J. Steroid Biochem. Mol. Biol. 97(1-2), 145-151 (2005).
74. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J. Cell. Biochem. 88(2), 363-371 (2003).
75. Luo W, Karpf AR, Deeb KK et al. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer. Cancer Res. 70(14), 5953-5962 (2010).
76. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25- dihydroxyvitamin D(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J. Urol. 165(4), 1319-1324 (2001).
77. Zhang Z, Kovalenko P, Cui M, Desmet M, Clinton SK, Fleet JC. Constitutive activation of the mitogen-activated protein kinase pathway impairs vitamin D signaling in human prostate epithelial cells. J. Cell. Physiol. 224(2), 433-442 (2010).
78. Serda RE, Bisoffi M, Thompson TA, Ji M, Omdahl JL, Sillerud LO. 1alpha,25- dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. Prostate 68(7), 773-783 (2008).
79. Zhao XY, Peehl DM, Navone NM, Feldman D. 1alpha,25- dihydroxyvitamin D3 inhibits prostate cancer cell growth by androgen-dependent and androgen-independent mechanisms. Endocrinology 141(7), 2548-2556 (2000).
80. Gocek E, Studzinski GP. Vitamin D and differentiation in cancer. Crit. Rev. Clin. Lab. Sci. 46(4), 190-209 (2009).
81. Murthy S, Agoulnik IU, Weigel NL. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate 64(4), 362-372 (2005).
82. Chen TC, Wang L, Whitlatch LW, Flanagan JN, Holick MF. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J. Cell. Biochem. 88(2), 315-322 (2003).
83. Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16(2), 83-95 (2005).
84. Shaukat A, Scouras N, Schunemann HJ. Role of supplemental calcium in the recurrence of colorectal adenomas: a metaana lysis of randomized controlled trials. Am. J. Gastroenterol. 100(2), 390-394 (2005).
85. Tseng M, Breslow RA, Graubard BI, Ziegler RG. Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. Am. J. Clin. Nutr. 81(5), 1147-1154 (2005).
86. Rodriguez C, Mccullough ML, Mondul AM et al. Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol. Biomarkers Prev. 12(7), 597-603 (2003).
87. Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: a historical perspective. Pediatrics 112(2), e132-e135 (2003).
88. Eelen G, Gysemans C, Verlinden L et al. Mechanism and potential of the growth-inhibitory actions of vitamin D and analogs. Curr. Med. Chem. 14(17), 1893-1910 (2007).
89. Kumagai T, O'Kelly J, Said JW, Koeffler HP. Vitamin D2 analog 19-nor-1,25- dihydroxyvitamin D2: antitumor activity against leukemia, myeloma, and colon cancer cells. J. Natl Cancer Inst. 95(12), 896-905 (2003).
90. Schwartz GG, Eads D, Naczki C, Northrup S, Chen T, Koumenis C. 19-nor-1 alpha,25-dihydroxyvitamin D2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol. Ther. 7(3), 430-436 (2008).
91. Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 60(8), 2304-2312 (2000).
92. Macejova D, Ondkova S, Jakubikova L et al. MNU-induced mammary gland carcinogenesis: chemopreventive and therapeutic effects of vitamin D and seocalcitol on selected regulatory vitamin D receptor pathways. Toxicol. Lett. 207(1), 60-72 (2011).
93. Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Results Cancer Res. 164, 273-288 (2003).
94. Bhatia V, Saini MK, Shen X et al. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol. Cancer Ther. 8(7), 1787-1798 (2009).
95. Canil CM, Moore MJ, Winquist E et al. Randomized Phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 23(3), 455-460 (2005).
96. Marchiani S, Bonaccorsi L, Ferruzzi P et al. The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J. Cancer Res. Clin. Oncol. 132(6), 408-416 (2006).
97. Crescioli C, Ferruzzi P, Caporali A et al. Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a Phase II clinical trial in patients with benign prostate hyperplasia. Eur. J. Endocrinol. 150(4), 591-603 (2004).
98. Scardino PT. The prevention of prostate cancer - the dilemma continues. N. Engl. J. Med. 349(3), 297-299 (2003).
99. Eelen G, Verlinden L, Bouillon R, De Clercq P, Munoz A, Verstuyf A. CD-ring modified vitamin D3 analogs and their superagonistic action. J. Steroid Biochem. Mol. Biol. 121(1-2), 417-419 (2010).
100. Muindi JR, Peng Y, Potter DM et al. Pharmacokinetics of high-dose oral calcitriol: results from a Phase 1 trial of calcitriol and paclitaxel. Clin. Pharmacol. Ther. 72(6), 648-659 (2002).
101. Beer TM, Munar M, Henner WD. A Phase I trial of pulse calcitriol in patients with refractory malignancies: pulse dosing permits substantial dose escalation. Cancer 91(12), 2431-2439 (2001).
102. Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol. 21(1), 123-128 (2003).
103. Blanke CD, Beer TM, Todd K, Mori M, Stone M, Lopez C. Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer. Invest. New Drugs 27(4), 374-378 (2009).
104. Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a Phase I/II study. J. Urol. 174(3), 888-892 (2005).
105. Chang SS. Treatment options for hormone-refractory prostate cancer. Rev. Urol. 9(Suppl. 2), S13-S18 (2007).
106. Trump DL, Deeb KK, Johnson CS. Vitamin D: considerations in the continued development as an agent for cancer prevention and therapy. Cancer J. 16(1), 1-9 (2010).
107. Beer TM, Javle M, Lam GN, Henner WD, Wong A, Trump DL. Pharmacokinetics and tolerability of a single dose of DN-101, a new formulation of calcitriol, in patients with cancer. Clin. Cancer Res. 11(21), 7794-7799 (2005).
108. Beer TM, Javle MM, Ryan CW et al. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer. Cancer Chemother. Pharmacol. 59(5), 581-587 (2007).
109. Chan JS, Beer TM, Quinn DI et al. A Phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 102(11), 1601-1606 (2008).
110. Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT investigators. J. Clin. Oncol. 25(6), 669-674 (2007).
111. Scher HI, Jia X, Chi K et al. Randomized, open-label Phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J. Clin. Oncol. 29(16), 2191-2198 (2011).
112. Fakih MG, Trump DL, Muindi JR et al. A Phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors. Clin. Cancer Res. 13(4), 1216-1223 (2007).
113. Muindi JR, Johnson CS, Trump DL, Christy R, Engler KL, Fakih MG. A Phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 65(1), 33-40 (2009).
114. Chadha MK, Tian L, Mashtare T et al. Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer. Cancer 116(9), 2132-2139 (2010).
115. Dalhoff K, Dancey J, Astrup L et al. A Phase II study of the vitamin D analogue seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 89(2), 252-257 (2003).
116. Evans TR, Colston KW, Lofts FJ et al. A Phase II trial of the vitamin D analogue seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br. J. Cancer 86(5), 680-685 (2002).
117. Schwartz GG, Hall MC, Stindt D, Patton S, Lovato J, Torti FM. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgenin-sensitive prostate cancer. Clin. Cancer Res. 11(24 Pt 1), 8680-8685 (2005).
118. Colli E, Rigatti P, Montorsi F et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur. Urol. 49(1), 82-86 (2006).
119. Liu G, Oettel K, Ripple G et al. Phase I trial of 1alpha-hydroxyvitamin D(2) in patients with hormone refractory prostate cancer. Clin. Cancer Res. 8(9), 2820-2827 (2002).
120. Liu G, Wilding G, Staab MJ et al. Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. Clin. Cancer Res. 9(11), 4077-4083 (2003).
121. Attia S, Eickhoff J, Wilding G et al. Randomized, double-blinded Phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Clin. Cancer Res. 14(8), 2437-2443 (2008).
122. McGrath JJ, Saha S, Burne TH, Eyles DW. A systematic review of the association between common single nucleotide polymorphisms and 25-hydroxyvitamin D concentrations. J. Steroid Biochem. Mol. Biol. 121(1-2), 471-477 (2010).
123. Berndt SI, Dodson JL, Huang WY, Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J. Urol. 175(5), 1613-1623 (2006).
124. Raimondi S, Johansson H, Maisonneuve P, Gandini S. Review and meta-ana lysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 30(7), 1170-1180 (2009).
125. Li H, Stampfer MJ, Hollis JB et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 4(3), e103 (2007).
126. Tang C, Chen N, Wu M, Yuan H, Du Y. FOK1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-ana lysis. Breast Cancer Res. Treat. 117(2), 391-399 (2009).
127. Mccullough ML, Bostick RM, Mayo TL. Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu. Rev. Nutr. 29, 111-132 (2009).
128. Lowe LC, Guy M, Mansi JL et al. Plasma 25-hydroxy vitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur. J. Cancer 41(8), 1164-1169 (2005).
129. Guy M, Lowe LC, Bretherton-Watt D et al. Vitamin D receptor gene polymorphisms and breast cancer risk. Clin. Cancer Res. 10(16), 5472-5481 (2004).
130. Chen L, Davey Smith G, Evans DM et al. Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. CancerEpidemiol. Biomarkers Prev. 18(11), 2874-2881 (2009).
131. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S, Peters U. Comprehensive association ana lysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol. Biomarkers Prev. 16(10), 1990-1999 (2007).
132. Hawkins GA, Cramer SD, Zheng SL et al. Sequence variants in the human 25-hydroxyvitamin D3 1-alphahydroxylase (CYP27B1) gene are not associated with prostate cancer risk. Prostate 53(3), 175-178 (2002).
133. Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL. Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 18(6), 1929-1933 (2009).
134. Ahn J, Albanes D, Berndt SI et al. Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 30(5), 769-776 (2009).
135. Holt SK, Kwon EM, Koopmeiners JS et al. Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 70(13), 1448-1460 (2010).
136. Dong LM, Ulrich CM, Hsu L et al. Vitamin D related genes, CYP24A1 and CYP27B1, and colon cancer risk. Cancer Epidemiol. Biomarkers Prev. 18(9), 2540-2548 (2009).
137. ClinicalTrials.gov. www.clinicaltrials.gov (Accessed 9 April 2012)